RxDoctor Payments DataLook up a doctor →

Renee Roth

Acute Care · Dayton, OHNPI 1295975266

Payments from drug & device makers

$8,561in general payments, 2019–2025

Across 421 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$705
  • Novartis$559
  • Johnson & Johnson$539
  • Daiichi Sankyo Inc.$499
  • Exelixis Inc.$394
  • Bristol Myers Squibb$393
  • plus $5K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck35$705
Novartis33$559
Johnson & Johnson27$539
Daiichi Sankyo Inc.26$499
Exelixis Inc.3$394
Bristol Myers Squibb23$393
Lilly USA, LLC16$382
AbbVie19$375
Incyte Corporation16$314
Pharmacyclics LLC, An Abbvie Company13$312
AstraZeneca(2 entities)15$293
Sanofi11$291
Takeda Pharmaceuticals U.S.A., Inc.10$209
Tersera Therapeutics LLC9$190
GSK10$190
Eisai Inc.10$188
Jazz Pharmaceuticals Inc.6$176
Genentech USA, Inc.13$161
Amgen9$143
Bayer8$136
Regeneron Healthcare Solutions, Inc.7$134
Pfizer7$126
E.r. Squibb & Sons, L.L.C.5$115
Beigene USA, Inc.6$115
Gilead(2 entities)7$112
ADC Therapeutics America, Inc.6$107
Stemline Therapeutics Inc.4$93
Ipsen Biopharmaceuticals, Inc5$91
Kyowa Kirin, Inc.5$90
Seagen Inc.4$83
Astellas Pharma US Inc4$78
Genmab U.S., Inc.3$74
Servier Pharmaceuticals LLC4$73
Blueprint Medicines Corporation4$63
Rigel Pharmaceuticals, Inc.4$60
Sumitomo Pharma America, Inc.2$57
Foundation Medicine, Inc.2$50
Morphosys, US Inc.2$48
Adaptive Biotechnologies Corporation2$45
Pharmaessentia USA Corporation2$42
Cumberland Pharmaceuticals, Inc.2$40
Pharmacosmos Therapeutics Inc.2$37
Karyopharm Therapeutics Inc.2$36
Sobi, Inc2$33
Sun Pharmaceutical Industries Inc.1$30
Boehringer Ingelheim1$27
Recordati_rare_diseases_inc.1$25
Fresenius Kabi USA, LLC1$24
AVEO Pharmaceuticals, Inc.1$21
Array Biopharma Inc1$20
Deciphera Pharmaceuticals Inc.1$20
Fennec Pharmaceuticals, Inc.1$19
Menarini Silicon Biosystems, Inc.1$18
Amneal Pharmaceuticals LLC1$18
Taiho Oncology, Inc.1$17
Immunocore Limited1$17
Dendreon Pharmaceuticals LLC1$16
Springworks Therapeutics, Inc.1$15
G1 Therapeutics, Inc.1$15
Puma Biotechnology, Inc.1$12

How this compares

$8,561 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio →

Medicare billing

Part B allowed, 2024
$229,663
Medicare patients
182
Services billed
13,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Dayton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →